Cytovance Biologics Adds Cell Line Development Services

Cytovance Biologics, a U.S.-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, has expanded its mammalian cell culture capabilities with the addition of cell line development services, strengthening its ability to provide a seamless path from DNA to IND submission for its customers.

Building on the recent launch of formulation development capabilities, the addition of in-house cell line development further strengthens Cytovance’s integrated offering—enabling a more seamless, efficient, and forward-looking approach to biologics development from discovery through commercialization.

“Our clients are looking for high-yield, speed and continuity,” said Shelly Gulati, Senior Scientist, Mammalian Process Development at Cytovance Biologics. “Bringing cell line development in-house allows us to provide them with a truly integrated ‘one-stop-shop’ experience, eliminating external handoffs, and making faster, data-driven decisions that strengthen manufacturability from the start.”

With headline titers reaching up to 10 g/L for monoclonal antibodies, Cytovance enters the cell line development market as a leading performer in CHO expression systems. The platform’s high titers enable faster process development, reduce manufacturing costs per gram, and accelerate timelines without compromising product quality.

Ping Zhang, CEO of Cytovance Biologics, said, “By offering in-house cell line development, we are helping clients move from concept to clinic, eliminating barriers, unlocking productivity and building a smarter, more resilient development path.”